Edition:
United States

Acer Therapeutics Inc (ACER.OQ)

ACER.OQ on NASDAQ Stock Exchange Capital Market

19.30USD
23 May 2018
Change (% chg)

$0.30 (+1.58%)
Prev Close
$19.00
Open
$18.74
Day's High
$19.30
Day's Low
$18.74
Volume
879
Avg. Vol
4,291
52-wk High
$21.71
52-wk Low
$5.70

Summary

Name Age Since Current Position

Christopher Schelling

41 2017 President, Chief Executive Officer, Director

Harry Palmin

47 2017 Chief Financial Officer

Jason Kneeland

2017 Vice President - Finance, Controller

Stacey Bain

2018 Vice President - Clinical Operations

Terrie Kellmeyer

2017 Vice President - Clinical Science

John Klopp

2018 Vice President - Manufacturing

Kristin Mulready

2018 Vice President - Program and Alliance Management

Matt Seibt

2018 Vice President - Market Access and Reimbursement

Kim Tharaldsen

2018 Senior Director of Marketing

William Andrews

51 2017 Chief Medical Officer

Donald Joseph

62 2018 Secretary and Chief Legal Officer

Jason Amello

2017 Director

Stephen Aselage

2017 Director

Hubert Birner

2017 Director

John Dunn

2017 Director

Michelle Griffin

2017 Director

Luc Marengere

2017 Director

Biographies

Name Description

Christopher Schelling

Mr. Christopher Schelling serves as President, Chief Executive Officer, Director of the Company. Mr. Schelling founded Private Acer in December 2013 and has served as a director of Private Acer since that time. From December 2013 to February 2016, Mr. Schelling served as Private Acer’s chief operating officer, and since February 2016 has served as Private Acer’s president and chief executive officer. Mr. Schelling also founded Apanii Consulting, LLC, a pharmaceutical and biotechnology consulting, in December 2012 and serves as the chief executive officer of that company. Prior to founding Apanii Consulting, Mr. Schelling served as executive director of BioMarin Pharmaceutical Inc., a biotechnology company, or BioMarin, where he worked on strategic marketing. Mr. Schelling earned a B.A. in biology from Carroll College.

Harry Palmin

Mr. Harry S. Palmin serves as Chief Financial Officer of the Company. Mr. Palmin has served as Private Acer’s acting chief financial officer since February 2016. Prior to that, Mr. Palmin served as the president, chief executive officer and a director of Private Acer from its founding in December 2013 until February 2016. Prior to joining Private Acer, Mr. Palmin served in a variety of roles at Novelos Therapeutics, Inc., a pharmaceutical company, including president and director from 1998 to October 2013, chief executive officer from January 2005 to October 2013 and acting chief financial officer from 1998 to September 2005. Mr. Palmin earned a B.A. in economics from Brandeis University and a M.A. in international economics and finance from the Brandeis University International Business School.

Jason Kneeland

Mr. Jason Kneeland is Vice President - Finance, Controller of the Company. He brings nearly 20 years of progressive experience in the corporate finance leadership of technology and related companies. Prior to joining Acer, Mr. Kneeland was VP Finance at TechTarget, Inc., a public company with 700 employees and $100M of annual revenue, where he led a team responsible for the day-to-day finance and accounting operations, as well as several key initiatives around revenue recognition and systems implementations. Prior to TechTarget, Mr. Kneeland was a Senior Manager at CFGI, where he assisted domestic and international bio-tech and technology clients with public offerings, mergers and acquisitions and other complex accounting, reporting and internal-control matters. Prior to that, Mr. Kneeland was Director of Technical Accounting of a multi-billion-dollar publicly traded retail pharmacy and pharmacy benefit management company. He has fulfilled various accounting and reporting roles with publicly traded companies in the technology industry since beginning his career in the audit practice of KPMG LLP. Mr. Kneeland is a Certified Public Accountant in the state of Massachusetts and holds a Bachelor of Science in Accounting from Johnson & Wales University.

Stacey Bain

Dr. Stacey Bain is Vice President - Clinical Operations of the Company. Dr. Bain joined Acer as Vice President, Clinical Operations in February 2018. She brings with her 20 years of international clinical operational and drug development experience in the pharmaceutical, biotechnology, and clinical research organization settings. Dr. Bain has managed or played an integral role in over 25 clinical trials, including both domestic and global studies. She oversaw two global Phase 3 oncology programs simultaneously with a combined budget of $75 million. Dr. Bain's experience includes management of various cross functional clinical development areas (clinical operations, drug safety, regulatory, data management, programming, biostatistics, medical writing, and third-party vendors). Previously, she held key leadership roles at Amunix Operating Inc., BioNumerik Inc., QLT Inc., InClin Inc., and PPD Development. Dr. Bain received a B.S. degree in Biomedical Science from Texas A&M University and a Ph.D. degree in Medical Science from Texas A&M College of Medicine.

Terrie Kellmeyer

Ms. Terrie Kellmeyer, Ph.D., is Vice President - Clinical Science of the Company. Dr. Kellmeyer joined Acer as Vice President, Clinical Science in December 2017. She brings to Acer over 17 years of experience in the pharmaceutical industry spanning the areas of Clinical Development, Regulatory Affairs, Medical Writing and Medical Affairs. Over her career, Dr. Kellmeyer filed three NDAs, worked on a Brand Team preparing for product launch, and led clinical development programs. Prior to joining Acer, she served as Executive Director of Medical Writing and Scientific Communications at Intercept Pharmaceuticals where she was instrumental in leading scientific content and optimizing timelines for an NDA submission, served as a key member of the team for a positive Advisory Committee meeting, and oversaw all externally and internally facing scientific communications. Previously, Dr. Kellmeyer held positions of increasing responsibility in Clinical Development and Regulatory Affairs at Amylin Pharmaceuticals and Gen-Probe, Inc. She received a B.S. degree in Biotechnology from Rochester Institute of Technology and a Ph.D. degree in Cellular and Molecular Biology from SUNY Health Science Center at Syracuse.

John Klopp

Mr. John S. Klopp is Vice President - Manufacturing of the Company. He brings 15 years of experience in the biopharmaceutical industry developing small molecule drug candidates in positions ranging from research to process development to contract manufacturing management. Mr. Klopp has spent the last 11 years working on the development and commercialization of orphan drugs at BioMarin Pharmaceutical and later Ultragenyx Pharmaceutical. His expertise includes selecting and managing contract manufacturing sites producing drug substance and various oral dosage forms including associated sponsor clinical and commercial CMC regulatory strategy. Mr. Klopp received a B.S. degree in Chemistry from Pennsylvania State University and a M.S. degree in Chemistry from University of California at Berkeley.

Kristin Mulready

Ms. Kristin Mulready is Vice President - Program and Alliance Management of the Company. She has over 20 years of biotechnology experience with expertise in executional strategy and team leadership. Prior to joining Acer, she was Senior Director of Program and Alliance Management at Mersana Therapeutics where she launched the function with responsibility for establishing and leading governance and teams, driving the business processes to advance the multiple internal and partnered programs, and ensuring efficiency in delivering on goals across the portfolio. Previously, she held roles of increasing responsibility at ImmunoGen, Inc. spanning Program Management, Alliance Management and Discovery Research. Mrs. Mulready earned her B.A. degree in Biology from Colby-Sawyer College and her M.S. degree in Management from Lasell College.

Matt Seibt

Mr. Matt Seibt is Vice President - Market Access and Reimbursement of the Company. Mr. Seibt joined Acer as Vice President, Market Access and Reimbursement in April 2018. He has over 22 years of health care industry experience, with 15 years of specialization in managed care market access and reimbursement. During his career, Mr. Seibt has successfully launched 18 products in primary care, specialty, and rare diseases. Prior to joining Acer, he was the Director of Account Management, where he led a field market access team dedicated to securing distribution, formulary coverage, and reimbursement of Biogen's portfolio in hemophilia, multiple sclerosis, and spinal muscular atrophy. Previously, Mr. Seibt has held roles in sales, marketing, and market access at Pfizer, Vertex, PCA HealthPlans and PacifiCare. He received his B.A. degree in economics at The University of Texas and completed the healthcare leadership program at Portland State University.

Kim Tharaldsen

Ms. Kim Tharaldsen is Senior Director - Marketing of the Company. She brings to Acer over 16 years of experience managing teams and brands for companies in the pharmaceutical, diagnostic, and device markets. From product launch to end of life planning and execution, Ms. Tharaldsen has managed brands through all phases of the product lifecycle across a number of therapeutic markets including Oncology, Genetics, Neurology and Gastrointestinal disorders. In addition to a deep clinical understanding of various conditions and solutions, she brings to Acer a diverse marketing skill set that has been cultivated by experience with products that range from small niche market entrants to blockbuster, multibillion dollar drugs. Ms. Tharaldsen has contributed to the success of such companies as Eisai, Myriad Genetics, Prometheus and Hologic. She has a BS in Biology, and a MBA in Innovation and Entrepreneurship from Felician University.

William Andrews

Mr. William T. Andrews is Chief Medical Officer of the company. He joins Acer Therapeutics as Chief Medical Officer after having worked in the biotech/pharmaceutical industry for 17 years in both Clinical Development and Medical Affairs in multiple therapeutic areas, with a focus and extensive experience in rare diseases. Dr. Andrews has significant medical marketplace and product launch experience, having served as the medical lead for six product launches, including Xopenex HFA®, Brovana®, Alvesco®, Omnaris®, Catena®, and Juxtapid®. Most recently, he provided strategic consulting services to rare disease companies in Clinical Development, Medical Affairs, Go-To-Market/Launch planning, and Business Development/Corporate Strategy. Previously, Dr. Andrews held senior leadership positions and positions of increasing responsibility at Aegerion Pharmaceuticals, Santhera Pharmaceuticals, Sepracor, and ClinQuest. He received his undergraduate degree in Biology from Harvard University and his M.D. degree from Yale University School of Medicine. Dr. Andrews practiced medicine for 7 years full-time and 11 years part-time in the Boston area as a board-certified Internist and an Attending Physician at Brigham and Women’s Hospital, and was on the Clinical Faculty at Harvard Medical School.

Donald Joseph

Mr. Donald Joseph is Secretary and Chief Legal Officer of the Company. About Don Joseph Mr. Joseph joined Acer as Chief Legal Officer and Secretary in April 2018. He has over 20 years of biopharmaceutical industry experience, including general counsel and senior management positions in biopharmaceutical and global health organizations. Mr. Joseph served as Chief Legal Officer and Board Secretary of KaloBios Pharmaceuticals, Inc., a publicly listed biopharmaceutical company. Prior to KaloBios, he was Chief Executive Officer, and before that, Chief Operating Officer of BIO Ventures for Global Health, or BVGH. Mr. Joseph is currently a member and Secretary of the BVGH board of directors, having served previously as its Chairman. He previously served as general counsel, corporate secretary, and in other senior management roles at publicly held biopharmaceutical companies, including Abgenix and Renovis. Mr. Joseph currently serves as lead independent director of Achieve Life Sciences, a publicly held pharmaceutical company. Before entering the life sciences industry, he practiced corporate law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world's largest law firms. Mr. Joseph received his J.D. degree from the University of Texas School of Law, with honors.

Jason Amello

Mr. Jason Amello serves as Director of Acer Therapeutics, Inc.

Stephen Aselage

Mr. Stephen J. Aselage serves as Director of Acer Therapeutics, Inc.

Hubert Birner

Dr. Hubert Birner serves as Director of the Acer Therapeutics, Inc.

John Dunn

Mr. John M. Dunn serves as Director of Acer Therapeutics, Inc.

Michelle Griffin

Ms. Michelle Griffin serves as Director of Acer Therapeutics, Inc.

Luc Marengere

Dr. Luc Marengere serves as Director of Acer Therapeutics, Inc.